Background:Hepatocellular carcinoma(HCC) cells often have hepatitis B virus(HBV)-DNA integration and can be targeted by T cells engineered to express HBV-specific T-cell receptors(TCR) as a means of therapy.However,pre-clinical in vitro characterizations of the engineered T cells were usually performed in artificial conditions that stray far from the physiologic or diseased liver setting.